Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:14 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Vaccination Plus Ontak in Patients With Metastatic Melanoma
NCT00515528 · University of Chicago · PHASE2 · terminated · last registry update 2021-01-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The immune monitoring data failed to demonstrate an improvement in any biologic endpoint with denileukin diftitox.” | – | Registry record, University of Chicago |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against EEF2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-12-02Results posted on the registry: National Cancer Institute (NCI), LMB-100 + Pembrolizumab (NCT03644550)
- 2021-12-02Also stopped (terminated): National Cancer Institute (NCI), LMB-100 + Pembrolizumab (NCT03644550)
- 2021-10-25Results posted on the registry: University of Louisville, Ipilimumab (NCT02009384)
- 2021-10-25Also stopped (terminated): University of Louisville, Ipilimumab (NCT02009384)
- 2021-02-02Results posted on the registry: National Cancer Institute (NCI), LMB-100 + Nab-Paclitaxel (NCT02810418)
- 2020-04-27Results posted on the registry: University of California, San Francisco, Gemcitabine + Navelbine (NCT00632827)
- 2020-04-27Also stopped (terminated): University of California, San Francisco, Gemcitabine + Navelbine (NCT00632827)
- 2020-03-18Results posted on the registry: Eisai Inc., Denileukin diftitox + Cyclophosphamide (NCT00211185)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision